(OTCBB: PBOTF)Ready To Move!!!

PENN BIOTECH INC.

 

Company Name: Penn Biotech Inc.

Stock Symbol: OTCBB: PBOTF

Current Price: $1.60

Shares Outstanding: 19,000,000

Approx. Float: 11,000,000

2 Week Target: $2.85

3 Month Target: $10.00

 

Penn Biotech Inc Overview:

 

Penn Biotech Inc. (PBOTF:BB) is in the process of 
a

transformation. 

  

The management has long established ties with Asia, 
on

both personal and business levels. The 
technology

behind the seed potato business of Penn was 
developed

in Korea, and Penn was able to license its 
development

 because of those 
management ties.

  

The transformation that is taking place is 
developing

the company into a technology holding company, 
by

acquiring other Asian technologies and bringing 
them

to the North American product markets and, by 
so

doing, building the company up to the point where 
its

shares would qualify to trade on a major US 
exchange.

In this way, US multiples can be realized on 
the

stock, and access gained to the vastly larger pools 
of

capital in the US.

 

To this end, the company has recently signed a 
letter

of intent to acquire all of the issued and 
outstanding

shares in another Korean technology 
company,

Traffic-ITS Co. Ltd., positioning Penn with two 
world

leading technologies in well established 
product

markets.

  

About the Technologies

 

First, Penn Biotech > ->  why should anyone be 
excited

about potatoes?

  

Well, the reasons are pretty basic: potatoes are 
the

second largest agricultural crop by value in 
the

world. Potatoes for consumption are grown from 
seed

stock developed through successive generations of 
seed

potatoes. Each successive generation 
yields

approximately ten times the number from the 
previous

generation, it is only economic to grow potatoes 
for

consumption from the sixth generation The 
production

cycle is thus very long, and subject to numerous 
risks

from disease and weather. 

The global market size of the seed potato industry 
was

approximately 35 million tones in 2002, which, at 
an

average price of US$290 per tonne, gives a 
total

market value of approximately US$10 The 
Canadian

market is worth about US$89 million, the US 
about

US$360 million.

 

So? What Penn> '> s technology does is to reduce 
the

cycle by at least one generation > ->  thus 
reducing

the time to market and the attendant risks. 
In

addition, because of the way in which the seeds 
are

propagated, each generation is as strong 
genetically

as the previous, unlike conventional methods. 
there

are numerous other, technical advantages that 
Penn

has, but these two are the essential 
ones.

 

Next, Traffic-ITS. The business sector is that 
of

intelligent transportation management > ->  ITS as the

industry abbreviation has it.

 

This is a truly huge industry > ->  
encompassing

everything from in-road traffic sensors, to GPS 
car

tracking systems, to traffic monitoring video 
cameras,

to > "> Amber Alert> ">  systems to LED 
traffic

lights. Traffic-ITS is the dominant company in 
this

industry in Korea, with sales having grown from 
US$7

to US$30 million in the last three years, and 
future

growth forecast at an increasing rate as the 
company

expands into the US and China.

 

The forecast from the US Department of 
Transportation

is for over US$210 billion to be spent in the 
next

decade on ITS in the US. China> '> s needs are 
even

larger, with spending currently running at over 
US$32

billion per year. 

  

Of the many companies in the industry, very few are 
in

all aspects of the business, and even for 
those

companies, such as Siemens, it is only a part of 
their

business. Traffic is a pure play in this 
massive

industry.

 

In summary, the combination of two Korean 
technologies

in two market sectors that are well developed 
and

growing rapidly represents a company and an 
investment

opportunity that deserves serious 
review.

 

 

 

NEWS HEADLINE FROM MARCH 16th 2004:   Penn 
Biotech

Inc. to Acquire Korean Technology Company  

 

Disclaimer:

 

All information provided in this newsletter 
pertaining

to

investing, stocks, securities must be understood 
as

information provided and not investment advice. 
This

newsletter advises all readers and subscribers to 
seek

advice from a registered professional 
securities

representative before deciding to trade in 
stocks

featured in

this newsletter or any stocks for that matter. 
All

statements and expressions of the companies 
featured

are not meant to be solicitation

or recommendation to buy, sell, or hold 
securities.

 

Investors should not rely solely on the 
information

contained in this newsletter. Rather, investors 
should

use the information contained in this newsletter as 
a

starting point for doing additional 
independent

research on the featured companies. Factual 
statements

in this newsletter are made as of the date stated 
and

are subject to change without notice. The receiver 
of

this newsletter shall not create, under 
any

circumstances, any implication that there has been 
no

change in the affairs of the company profiled 
since

the date of the review. The advertisements within 
this

newsletter are not to be construed as offers 
to

purchase securities in the

companies which may be the subject of 
such

advertisements pursuant to federal or state law or 
the

laws of any foreign jurisdiction. 
The

advertisements in this newsletter are believed to 
be

reliable, however this 
newsletter

disclaims any and all liability as to the 
completeness

or accuracy of the information contained in 
any

advertisement and for any omissions of material 
facts

from such advertisement.

 

Investing in micro-cap and growth securities is 
highly

speculative and carries an extremely high degree 
of

risk. It is possible that an

investor's investment may be lost or impaired due 
to

the speculative nature of the companies profiled. 

Information presented in this newsletter 
contain

"forward looking statements" within the meaning 
of

Section 27A of the

Securities Act of 1933 and Section 21B of 
the

Securities Exchange Act of 1934. Any statements 
that

express or involve discussions with respect 
to

predictions, expectations, beliefs, 
plans,

projections, objectives, goals, assumptions or 
future

events or performance are not statements of 
historical

fact and may be "forward looking statements." 
Forward

looking statements are based on 
expectations,

estimates and projections at the time the 
statements

are made that involve a number of risks 
and

uncertainties which could cause actual results 
or

events to differ materially from those 
presently

anticipated.

  

Forward looking statements in this action may 
be

identified through the use of words such 
as

"projects", "foresee", "expects'", 
"will,"

"anticipates," "estimates," "believes," 
"understands"

or that by statements indicating certain 
actions

"may," "could," or "might" 
occur.

 

Understand there is no guarantee past performance 
will

be indicative of future results. The accuracy 
or

completeness of the information in this newsletter 
is

only as reliable as the sources they were 
obtained

from. 

 

Investments in smallcap companies are generally 
deemed

to be highly speculative and to involve 
substantial

risk, making it appropriate for readers to 
consult

with professional investment advisors and to 
make

independent investigations before acting 
on

information published by this newsletter.  As in

compliance with the Securities Act of 1933, 
Section

17(b), any and all compensation received from 
a

company is publicly stated. 

 

There was no compensation paid for this 
profile.

921 
sauve court, n.vancouver - bc. 
canada.